CISION PR Newswire
Has China ever tried to replace universal international standards with its own standards in building the BRI?
China never tried to replace international standards in building the BRI.
FPT.AI is ranked Top 1 Global AI Platform 2023
FPT.AI is awarded Best AI Platform 2023 for its outstanding efforts in co-creating value with businesses. The platform has achieved high customer satisfaction and recognition from the international tech community. FPT.AI is an AI-powered platform with multiple solutions and is implemented by over 100 enterprises in 15 countries. The award further inspires the FPT.AI team to continue developing innovative AI products and positioning Vietnam as an AI center. FPT.AI has received various prestigious awards in the past.
Has China transferred its phased-out capacity to BRI partner countries and caused damage to their local environment?
BRI denies transferring phased-out capacity to partner countries, emphasizes green initiatives.
KPM Analytics Serves Bakers the Latest Innovation for Offline Product Quality Checks
KPM Analytics introduces TheiaVu E-Series Offline Vision Inspection System for bakeries, providing accurate measurements of baked goods' features.
JD.com Joins UN Global Compact's "Forward Faster" Initiative for 2030
JD.com, a supply chain-based provider, has joined the UN Global Compact's "Forward Faster" initiative, emphasizing its commitment to sustainability and global development. The company's CEO, Sandy Xu, met with the Assistant Secretary General of the United Nations and CEO of UN Global Compact during her visit to JD.com's headquarters in Beijing. JD.com has been recognized for its sustainable practices, such as green packaging and utilizing renewable energy. The company has also established the Green Impact Partners Alliance to promote green consumption. JD.com operates as a leading e-commerce company in China, serving millions of customers.
Zhimeng Biopharma CB03 Received Orphan Drug Designation from the US FDA – A Potassium Ion Channel Opener for Amyotrophic Lateral Sclerosis
Shanghai-based biopharmaceutical company Zhimeng received orphan drug designation from US FDA for its ALS treatment compound CB03. The compound is also being developed for other central nervous system diseases. A phase 1 study is currently ongoing to evaluate its safety and efficacy. Zhimeng hopes to bring a safer and more effective medicine to ALS patients worldwide. CB03 is a selective KCNQ2/3 potassium channel opener with potential as a treatment option for ALS and other CNS diseases. ALS is a neurodegenerative disease that causes loss of muscle control. Zhimeng is focused on developing drugs for chronic hepatitis B and severe neurological diseases.
Empowering Mochi Donut Makers with Augmented Reality: Chewco's Innovative AR Training Platform
Texture Maker introduces Chewco KaaS, an AR-based platform for mochi donut baking professionals.
Introducing UltraPure: Oraimo premium, 270-watt cordless vacuum
Oraimo launches lightweight cordless vacuum cleaner with detachable batteries and multiple modes.